Nervous System and Other Effects and the Corresponding Metal Levels in Rats Treated with Nanoparticulate and Dissolved Lead by Horváth, Edina et al.
106 · Neurotoxicity of NaNo- aNd dissolved lead
Nervous system aNd other effects aNd the correspoNdiNg 
metal levels iN rats treated with NaNoparticulate aNd 
dissolved lead
EDINA HORVÁTH1, ZSUZSANNA MÁTÉ1, PÉTER PUSZTAI2, ANDRÁS SÁPI2, ZOLTÁN 
KÓNYA2, EDIT PAULIK1, ANDRÁS PAPP1
1Department of Public Health, University of Szeged Faculty of Medicine. Szeged, Hungary
2Department of Applied and Environmental Chemistry, University of Szeged Faculty of Scence 
and Informatics, Szeged, Hungary
 
abstract: Lead (Pb) is, due to past and present uses, an abundant neurotoxic xenobiotic. 
Population-level exposure is typically oral while occupational exposure is frequently by in-
halation of metal fumes. To replicate exposure from these sources in rats, the animals were 
treated orally with Pb acetate (80 and 320 mg /kg b.w.) for 3 or 6 weeks, followed by intratra-
cheal (it.) application of PbO nanoparticles (2 mg/kg b.w.) for another 3 or 6 weeks. Parallel 
controls were vehicle treated. During the 3, 6 or 12 weeks of treatment, body weight gain was 
daily observed. The effect of oral Pb on that was slight but nanoparticles applied it. caused a 
marked drop in weight gain. Open field motility test at the end of treatment showed decreased 
rearing but increased ambulation and local activity. Finally, somatosensory cortical evoked 
potentials were recorded from the rats. Evoked potentials showed increased latency; where 
the increase, together with certain open field changes, was in significant linear relationship 
with brain Pb levels. Comparison to the applied doses showed that nanoparticulate Pb, ad-
ministered it., caused disproportionately strong brain Pb level increase, and, consequently, 
strong open field and electrophysiological alterations. The results underlined the importance 
of the physicochemical form of Pb in its toxicity and the extra risk from complex, oral and 
inhaled, exposure.
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INTRODUCTION
Due to its extensive uses in the past and today, lead (Pb) is one of the most common environ-
mental xenobiotics, present in soil, groundwater, air and foodstuffs. Roots, leafy vegetables, 
meats, dairy products or fishes may carry significant amounts of Pb, and represent major sourc-
es of population-wide oral Pb intake, together with drinking water (ATSDR, 1999). Emissions 
of lead processing/reprocessing industries may cause elevated local environmental levels which 
may lead to higher, sometimes life-threatening, food/waterborne intake (Haelfiger et al., 2009; 
Rosner and Markowitz, 2007). Ingested Pb is absorbed to 10-15 % (but in children to 50%); 
absorption of inhaled Pb is, in contrast, ca. 50% (Järup, 2003).
Inhalation of Pb is first of all an occupational hazard. Heated to 550-600°C, above its melting 
point of 327.5°C, Pb emits a lot of fumes, consisting mostly of lead oxide particles in the micron 
and submicron range. Inhalation of these particles results (due to efficient absorption mentioned 
above) in significant internal exposure both in humans and in experimental animals (Griffin et 
al., 1975a; 1975b). Submicron grains (so-called nanoparticles, NPs; with diameter less than 0.1 
µm) represent a small mass fraction in dust or fume samples, but the high number and large 
surface area of the NPs results in increased biological – including toxicological – activity. Com-
pared to microscopic particles, NPs have higher mobility within the organism, including direct 
access to the CNS, by penetrating tissue boundaries like the alveolar wall, capillary wall or the 
blood-brain barrier (BBB) (Oberdörster et al., 2000).
Absorbed Pb is accumulated in the CNS, first of all in the cortex and hippocampus. The thresh-
old of causing encephalopathy was earlier supposed to be at blood Pb levels of 1000-1200 μg/L 
in adults and 800-1000 μg/L in children (Chisolm, 1965). The adults’ threshold is still valid, but 
it has been realized that in children exposure even to low levels of Pb is associated with behav-
ioural abnormalities, learning impairment, decreased hearing, and impaired cognitive functions 
(Lidsky and Schneider, 2003). Accordingly, children’s blood Pb already at ≥ 100 μg/L justifies 
community-wide intervention (Rogan et al., 2001). Moreover, recent studies deny the existence 
of any “safe threshold” (Jakubowski, 2011).
In workers suffering from chronic Pb exposure, the documented neurologic effects included 
headache, lethargy, dizziness, lengthened reaction time, worsened cognitive and visuomotor 
performance, and slowed nerve conduction (Araki et al., 2000; Lille et al., 1998). Impaired 
postural balance was seen in workers exposed to airborne Pb (Yokoyama et al., 2002). Em-
ployees with inhalational and dermal exposure to inorganic and organic Pb had significant 
alterations of peripheral nerve conduction velocities and somatosensory evoked potentials 
(Jeyaratnam et al., 1985).
Real life exposure seldom comes from a single source or in a single form. Hence, the present 
study was based on combined Pb exposure, using oral and intratracheal administration (in 
analogy to food/waterborne environmental and inhaled occupational Pb load, respectively). 
The general and neurotoxic effects of Pb were investigated by behavioural and electrophysi-
ological methods.
108 · Neurotoxicity of NaNo- aNd dissolved lead
MATERIALS AND METHODS
Animals and treatment
Young adult male Wistar rats (200 ± 20 g) obtained from the university’s breeding centre were 
housed in a GLP-rated animal house (22 ± 1ºC, 30-60% relative humidity, 12 h light/dark cycle 
with light on at 06:00) with 2 or 3 rats in one cage (polypropylene, 27 x 39 cm, height 19 cm). 
The animals had free access to tap water (with 0.5 mg/L Pb content, as stated by the local wa-
terworks) and standard rodent chow.
To realize the combined experimental exposure mentioned above, various treatments were ap-
plied (summarized, with doses and group coding, in Table I). Orally treated rats received Pb 
acetate [Pb(CH3COO)2 3H2O; Sigma-Aldrich Hungary] daily for 3 and 6 weeks, dissolved in 
distilled water to 80 (low dose) and 320 (high dose) mg/ml concentration and administered by 
gavage in 1 ml/kg b.w. volume (groups PbL3, PbH3, PbL6, PbH6). In other groups, the same 
oral administration was followed by intratracheal application (daily for further 3 and 6 weeks) 
of a suspension of PbO NPs (2.0 mg/ml) instilled into the trachea of the rats (1 ml/kg b.w.) in 
brief ether anaesthesia (groups PbL3+3, PbH3+3, PbL6+6, PbH6+6). Vehicle control groups 
for oral (CW3, CW6) and oral + intratracheal (CWV3+3, CWV6+6) treatments, and an un-
treated control group (C), were also included, so that there were altogether 13 groups of 8 rats 
each. The doses and the time scheme were based on previous experience (oral dose: Pecze et al., 
2005; intratracheal dose: Oszlánczi et al., 2011, this paper also gives more detailed information 
on the administration procedure; time scheme: Horváth et al., 2012). The solution and nanosus-
pension used for treating the rats was freshly made every week and stored at 4°C.
The NPs of PbO (diameter 38.9±7.2 nm, Figure 1) were synthesized at the Department of Ap-
plied Chemistry, University of Szeged. A mixture of Pb(CH3COO)2 and NaOH was milled in 
a ball mill [reaction 1: Pb(CH3COO)2 + 2 NaOH → 2 Na(CH3COO) + Pb(OH)2]. After cal-
cination [reaction 2: Pb(OH)2 → PbO + H2O] the mixture was washed and filtered. Chemical 
purity of the NPs was determined by X-ray diffraction, and their particle size, by X-ray dif-
Figure 1. TEM image (left) and size histogram (right) of the PbO NPs.
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fraction and transmission electron microscopy. The NPs were suspended in a slightly viscous 
vehicle in order to prevent sedimentation (1% hydroxyethyl cellulose in PBS, pH 7.4; HEC) 
and the nanosuspension was mechanically resuspended immediately before each application.
During the whole study, the principles of the Ethical Committee for the Protection of An-
imals in Research of the University were strictly followed. The methods used in the ex-
periments were licensed by the authority competent in animal welfare issues under No. 
XXI./02039/001/2006.
General toxicological investigation
Before every administration, body weight of the animals was measured and their general state 
was observed, noting all signs of toxicity (aggression, lethargy, rough fur, etc.). Following elec-
trophysiological recording (see below), the animals were sacrificed by an overdose of urethane 
and were dissected. Organs – brain, liver, lungs, kidneys, spleen, femur – were removed and 
weighed, and relative organ weights, on the basis of brain weight, were calculated (brain weight 
was chosen because of the body weight effect of the treatments).
From the groups PbH3, PbH3+3, PbH6, PbH6+6 and the corresponding vehicle controls (CW3, 
CWV3+3, CW6, CWV6+6) 4 rats each were chosen randomly. Of these, whole blood (from the 
abdominal vein right after opening the abdominal cavity), brain and femoral bone samples were 
shock-frozen in liquid nitrogen and stored at -20°C, for later tissue Pb level determination (see 
below). Dissection and sample taking was done on separate days for each group which helped 
in avoiding cross-contamination.
To see the relationship of external dose, internal dose, and toxicological effects, rat-by-rat 
summed dose was calculated as the sum of daily amounts of Pb; based on actual body weight, 
the mg/ kg b. w. dose (Table 1) and the formula of the Pb compound used.
Behavioural investigation
The rats’ spontaneous locomotor behaviour pattern was assessed in an open field (OF) instru-
ment at the end of the treatment period, 2 days after the last Pb application, always between 
08:00 and 12:00. The OF box used was of 48x48x40 cm size and was equipped with two arrays 
of infrared beam gates at 1.5 and 12 cm above floor level, with 15 mm spacing between the 
beams (Conducta 1.0 System; Experimetria Ltd., Budapest, Hungary). After 20–30 min habitu-
ation in the dimly lit test room, the animals were put into the centre of the box one by one for a 
10 min session. From the beam interruptions, event counts and summed time of the basic activ-
ity forms (ambulation, local activity, rearing, immobility), as well as run length of ambulation, 
were computed as follows: more than 40 mm shift in the location of interrupted beams at the 
floor level during a time unit of 1 s was interpreted as horizontal activity; less shift, as local 
activity; and no shift at all, as immobility. Rearing was recorded if beams at floor level and at 
the higher level were interrupted simultaneously. In earlier works of us (Vezér et al., 2007) this 
method was found sensitive to metal-induced changes of motor activity.
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Electrophysiological investigation
Electrophysiological recording was done on the day following the OF test. Preparation for 
recording, and the recording itself, was performed in urethane anaesthesia (1000 mg/kg ip: 
Maggi and Meli, 1986). The left hemisphere was exposed, and a ball-tipped silver electrode 
was placed on the projection site of the contralateral whisker pad (barrel field: Waite, 2004) for 
recording evoked potentials (EPs). A pair of stimulating needle electrodes, delivering square 
electric pulses (3-4 V, 0.05 ms) was inserted among the whiskers. The punctum maximum of 
the EP was determined by single pulses, then one train of 50 pulses each at 1, 2 and 10 Hz fre-
quency was applied. The EPs were amplified (1000x, 1.6 and 1000 Hz filtering limits) and fed, 
with 8 kHz rate of digitizing, in a PC running the software Neurosys 1.11 for electrophysiologi-
cal recording and analysis (Experimetria Ltd., Budapest, Hungary). The 50 EPs per train were 
averaged, and onset latency measured, by means of the software.
From individual latency data, group means with standard deviation were calculated; these were 
further normalized to the corresponding vehicle control mean at 1 Hz stimulation frequency 
(measured in groups CW3, CWV3+3, CW6, CWV6+6) to make all group data comparable 
despite differences in the control values.
Determination of Pb level
Level of Pb was determined in the blood, brain and femoral bone samples mentioned above. 
Approximately 1 g of the samples was dried at 80°C to constant weight, and digested in 4 ml 
65% HNO3 at 90°C for 90 min. The digested matter was washed quantitatively into 100 ml 
measuring flasks and Pb determination was done from this diluted sample by inductively cou-
pled plasma mass spectrometry. The measurements were done at the laboratory of the MOL 
Hungarian Oil and Gas Company, on an Agilent 7500 ce instrument, according to the Hungar-
ian standard MSZ EN ISO 17294-2:2005.
Statistical analysis
The distribution of data was checked for normality by means of the Kolmogorov-Smirnov test. 
Data analysis was done by one-way ANOVA. Post hoc analysis of group differences was per-
formed by LSD test, setting the probability level at p > 0.05.
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table i.
Treatment scheme with group codes, doses and treatment times.
Groups and treatment Group codes Doses
Untreated control C ---
Vehicle control, 3 weeks CW3, Distilled water, oral
Vehicle control, 6 weeks CW6 Distilled water, oral
Oral Pb, low dose, 3 weeks PbL3 Pb(CH3COO)2  80 mg /kg b.w., oral1 
Oral Pb, high dose, 3 weeks PbH3 Pb(CH3COO)2  320 mg /kg b.w., oral2 
Oral Pb, low dose, 6 weeks PbL6 Pb(CH3COO)2  80 mg /kg b.w., oral
Oral Pb, high dose, 6 weeks PbH6 Pb(CH3COO)2  320 mg /kg b.w., oral
Combined vehicle control,
3+3 weeks CWV3+3 Distilled water, oral; then HEC intratracheal (it.)
Combined vehicle control,
6+6 weeks CWV6+6 Distilled water, oral; then HEC it.
Combined Pb, low dose,
3+3 weeks PbL3+3
Pb(CH3COO)2  80 mg /kg b.w. oral;
then PbO NPs 2 mg /kg b.w. it.3
Combined Pb, high dose,
3+3 weeks PbH3+3
Pb(CH3COO)2  320 mg /kg b.w. oral;
then PbO NPs 2 mg /kg b.w. it.
Combined Pb, low dose,
6+6 weeks PbL6+6
Pb(CH3COO)2  80 mg /kg b.w. oral;
then PbO NPs 2 mg/kg b.w. it.
Combined Pb, high dose,
6+6 weeks PbH6+6
Pb(CH3COO)2  320 mg /kg b.w. oral;
then PbO NPs 2 mg/kg b.w. it.
1 equal to 51 mg/kg b.w. lead
2 equal to 204 mg/kg b.w. lead
3 equal to 1.73 mg/kg b.w. lead
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t
a
b
l
e ii.
Sum
m
ed external Pb dose and tissue (blood, brain and fem
oral bone)
Pb levels in the various groups after 3, 6 and 12 w
eeks of Pb exposure according to Table I.
Sum
m
ed external 
dose (m
g Pb/rat)
Possibly absorbed 
am
ount (m
g Pb/rat) 1
Tissue Pb levels (µg/kg)
G
roups
B
lood
B
rain
Fem
ur
2
C
W
3
--
588.94 ± 100.41
546.28 ± 78.35
--
PbH
3
710.29±50.55
71.03±5.06
2739.29 ± 622.96
3136.99 ± 315.61 ***
259042.87 ± 40559.55 ***
C
W
V
3+3
--
--
520.44 ± 96.79
714.40 ± 484.34
--
PbH
3+3
796.41±57.81
96.57±7.02
9616.74 ± 1979.04 ***
5894.15 ± 548.82 ***
###
339026.55 ±79372.43 ***
C
W
6
--
856,69±145,82
659.34 ± 145.97
--
PbH
6
1675.23±67.67
167.52±6.77
7464.30 ± 3076.79 **
##
5654.01 ± 909.01 ***
###
263573.42 ± 15850.43 ***$
C
W
V
6+6
--
644.76 ± 138.62
515.98 ± 29.42
437.75 ± 18.96 
PbH
6+6
1819.80±83.51
197.66±70.24
15229.64 ± 4848.66 ***
###♦°
7182.00 ± 1342.53 ***
###♦°
399829.06 ± 65925.23 ***
#♦♦
M
ean±SD
, n=4.
*, **, ***: p < 0.05, 0.01, 0.001 PbH
3 vs. C
W
3; PbH
3+3 vs. C
W
V
3+3; PbH
6 vs. C
W
6; PbH
6+6 vs. C
W
V
6+6
#, ##, ###: p < 0.05,0.01, 0.001 PbH
3+3, PbH
6, PbH
6+6 vs. PbH
3;
♦: p <
 0.05 P
bH
6+
6 vs. P
bH
6
°: p <
 0.05 P
bH
6+
6 vs. P
bH
3+
3
$: p <0.05 PbH
3+3 vs. PbH
6
1C
alculated w
ith the absorption percentages in Järup (2003): 10%
 for ingested and 50%
 for inhaled lead.
2F
em
ur control P
b levels w
ere m
easured only in sam
ples of the 6+
6 w
eeks vehicle control (C
W
V
6+
6), due to financial lim
itations, and all data of treated rats’ fem
ur P
b w
ere 
com
pared to that. As, how
ever, rats in this group had the longest period to accum
ulate Pb from
 the environm
ental background, Pb level in C
W
V6+
6 w
as an obvious acceptable 
upper estim
ate of other vehicle treated rats’ levels.
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table iii.
Relative change of the latency of somatosensory evoked potentials
in the various treatment groups.
Groups Stimulation frequency
1Hz 2Hz 10Hz
CW3 1.00 ± 0.05 0.96 ± 0.04 1.04 ± 0.06
PbL3 0.99 ± 0.06 1.02 ± 0.08   1.08 ± 0.05 °
PbH3 1.03 ± 0.06 1.06 ± 0.04    1.12 ± 0.04 °° 
CWV3+3 1.00 ± 0.04 1.03 ± 0.06 1.05 ± 0.03
PbL3+3 1.01 ± 0.05 1.03 ± 0.04    1.13 ± 0.04 *°° 
PbH3+3 1.05 ± 0.04   1.10 ± 0.03 *°      1.15 ± 0.04 **°°
CW6 1.00 ± 0.03 1.01 ± 0.03 1.05 ± 0.02
PbL6 1.04 ± 0.03 1.06 ± 0.03   1.11 ± 0.04 °
PbH6 1.07 ± 0.02 1.13 ± 0.02     1.15 ± 0.02 *°°
CWV6+6 1.00 ±0.03 1.02 ± 0.03    1.05 ± 0.02 °
PbL6+6 1.06 ± 0.03  1.08 ± 0.03 *       1.13 ± 0.03 **°°
PbH6+6 1.07 ± 0.03   1.11 ± 0.03 **°      1.17 ± 0.05 **°°
Mean±SD, n=8.
*,**,***: p < 0.05, 0.01, 0.001  PbL3+3, PbH3+3 vs. CWV3+3; PbH6 vs. CW6; PbL6+6, PbH6+6 vs. CWV6+6
°,°°: p < 0.05, 0.01 vs. latency with 1 Hz stimulation within a treatment group.
RESULTS
General toxicity
In Figure 2, body weight gain of the groups C, CWV6+6, PbH3+3, PbH6 and PbH6+6 is com-
pared (the data of CWV3+3 were practically identical to those of CWV6+6 and were left out 
from the graph to avoid crowding). Weight gain deficit vs. controls on 6 weeks oral Pb treat-
ment (PbH6 and the first part of PbH6+6) and on the 6 weeks combined treatment (PbH3+3) 
was similar although the daily amount of Pb administered it. was much lower than the amounts 
given orally. And, the onset of it. application (marked by arrows at the corresponding groups in 
Figure 2) caused an abrupt drop in body weight gain, first of all in group PbH6+6. Later on, the 
slope of weight gain in the combined treatment groups (PbH3+3, PbH6+6) was again as before 
the onset of it. application, that is why the plot of daily weight gain (total weight increase divid-
ed by the numbers of days between start of treatment and sacrifice) against calculated summed 
dose (external dose) shown in Figure 3 gave a fair linear relationship.
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All Pb-treated groups showed significantly increased Pb levels in blood, brain and bone (fe-
mur) samples at the end of the experiment (Table II). Brain Pb levels (Figure 4A) as a meas-
ure of the internal dose likely to induce neuro-functional effects showed, besides a basic lin-
earity, clear dependence on the physicochemical form: a little plus Pb administered in form of 
PbO NPs caused disproportionately high elevation of brain Pb. Bone Pb levels, representing 
whole-body internal dose, depended much more on the summed dose (Figure 4B).
Due to the effect of the treatments on body weight, relative weight data based on brain weight 
were evaluated. Relative weight of the lungs increased significantly in each group receiving Pb 
NPs (CWV3+3: 1.21 ± 0.29, PbL3+3: 2.52 ± 0.30, PbH3+3: 2.38 ± 0.32; p < 0.001 vs. CWV 
for both treated groups; CWV6+6:1.42 ± 0.11, PbL6+6: 2.87 ± 0.35, PbH6+6: 3.02 ± 0.56; 
p < 0.001 vs. CWV for both treated groups). Relative kidney weight increased significantly vs. 
the corresponding vehicle control in PbH3 (1.36 ± 0.19 vs. 1.18 ± 0.04, p < 0.05) PbH3+3 (1.54 
± 0.18 vs. 1.34 ± 0.12, p < 0.05), PbH6 (1.76 ± 0.46 vs. 1.29 ± 0.18, p < 0.05), as well as in 
PbL6+6 (1.59 ± 0.16) and PbH6+6 (1.63 ± 0.12) vs. CWV6+6 (1.32 ± 0.16, p < 0.001 for both 
treated groups). Other organs showed no significant alteration of relative weight.
Figure 2. Time course of the rats’ body weight gain. Mean values, n=8. The arrows denote the onset
of intratracheal application of PbO NPs. For group codes, see Table I.
*: p < 0.05 vs. C; #, ##: p < 0.05, 0.01 vs. CWV6+6
Figure 3: Relationship of individual treated rats’ calculated daily weight gain to their calculated summed
Pb dose. The data plotted are of the same 4 animals per group whose data are also shown in Figs. 4 and 6.
Light squares, PbH3; filled squares, PbH3+3; light triangles, PbH6; filled triangles, PbH6+6. Insert:
equation and R2 of the fitted line; *: p < 0.05 (F-test for the linear fit).
y = -0,0012x + 6,1437
R2 = 0,5743*
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Figure 4. Relationship of brain (A) and femoral bone (B) Pb level in individual treated rats to their
calculated summed Pb dose. Insert and data point marking as in Fig. 3.
Neurotoxicity
Open field motility: The time spent with immobility, local activity and ambulation was in-
creased in the treated groups, significantly only in PbH6 and PbH6+6. In these groups, dimin-
ished rearing was also significant (Figure 5). The dependence of OF motility on internal (brain) 
Pb doses is shown in Figure 6D.
Cortical evoked potentials: The latency of SS EPs was significantly lengthened in each treat-
ment group vs. their controls (Table III). The data suggested that EP latency had a similar rela-
tionship to external Pb dose as the brain Pb levels did (see Figure 6A-C). Plotting the individual 
latency values against the same rat’s brain Pb level indeed showed fair linear correlation (R2 
> 0.25) but the data points representing rats of group PbH3+3 (filled squares) and PbH6 (light 
triangles) were in overlap; indicating that a lower overall dose, if it was partly in NP form, had 
ca. the same effect as a higher dose of dissolved Pb given orally. The same holds true also for 
OF motility and brain Pb levels (Figure 6D).
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Figure 5. Data of open field motility in rats treated with Pb by the
6 and 6+6 weeks scheme and the corresponding controls. Mean+SD, n=8.
*, **, ***: p < 0.05, 0.01, 0.001 PbH6 vs. C; PbL6+6 vs. C; PbH6+6 vs. C (Rats in group C had
an open field session after 6 weeks, and another one after 12 weeks).
#, ### p < 0.05, 0.001 PbH6+6 vs. CWV6+6
X: p < 0.05 PbH6+6 vs. PbL6+6
Figure 6. Relationship of the latency of somatosensory evoked potential (A, B, C) and open field ambulation
distance (D) of individual treated rats and their brain Pb level. Insert and data point marking as in Fig. 3.
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DISCUSSION
The physicochemical form of Pb (dissolved or nanoparticulate) seemed to exert a substantial 
effect on several of the investigated toxicological parameters, and thus showed that the assump-
tion which the experiments were based on was correct.
Tissue Pb levels in blood and brain, indicating internal dose, were higher in group PbH3+3 
than in PbH6, although the overall treatment time was the same and the calculated summed 
applied dose and the possibly absorbed amount was approximately twice as high in PbH6 than 
in PbH3+3 (applied dose: 1,675.23 ± 67.67 mg Pb/rat vs. 796.41 ± 57.81 mg Pb/rat; absorbed 
amount: 167.52 ± 6.77 mg Pb/rat vs. 96.57 ± 7.02 mg Pb/rat; see Table II). Similarly, the differ-
ence in blood and brain levels of PbH3+3 vs. PbH3, and PbH6+6 vs. PbH6, was much higher 
than the difference of the corresponding total amounts of Pb (summed external dose, mg Pb / 
rat) given orally and intratracheally. In parallel with that, latency lengthening of SS EP (Table 
III) in PbH3+3 and PbH6 was nearly equal, and in PbL3+3 was somewhat more than in PbL6 
– even though the summed external dose was higher in the groups with oral application only. 
The correlation of SS EP latency (Figure 6A-C) and OF ambulation distance (Figure 6D) with 
brain Pb level (i.e. internal dose) also supported that the NP form of Pb had a disproportionately 
strong influence on central nervous functions. Other toxicological parameters, however, i.e. Pb 
level in the femoral bone and daily body weight gain, were simply dependent on the summed 
external dose, irrespective of the form.
The more-than-additive interaction of dissolved and nanoparticulate Pb in the neuro-functional 
effects, as described above, could be due to weakened BBB (a known effect of Pb: Goldstein et 
al., 1974). After weeks of effect by dissolved Pb, BBB may have been less able to exclude NPs. 
The extreme mobility and biological activity of NPs (Oberdörster et al., 2005) could in itself 
result in higher metal levels in the central nervous system, but comparison with one of our pre-
vious experiments (Oszlánczi et al., 2011) suggested that the preceding effect of dissolved Pb 
(which was important in examining the interaction of two different forms and exposure modes 
of the same environmental heavy metal, see Introduction) was of importance. In the cited ex-
periment, PbO NPs, highly similar to those used this time, was applied it. for 6 weeks in 4 mg/
kg b.w. dose and caused a relative increase of SS EP latency of ca. 1.05 (at 1 Hz stimulation 
frequency) while in the present work 3 weeks of 2 mg/kg b.w. were enough to cause a similar 
EP lengthening.
Oxidative stress induced by Pb, with ROS generation and membrane lipid peroxidation, was reported 
both in animals (Adonaylo and Oteiza, 1999; Patra et al., 2001) and humans (Ahamed and Siddiqui, 
2007). Damaged lipids lead to changes in fluidity and other properties of the cell membrane, disturb-
ing membrane- and receptor-bound phenomena (Coyle and Puttfarcken, 1993). The activity of as-
trocytic glutamate transporter is reduced both by membrane lipid peroxidation (Willmore and Ueda, 
2009) and direct effect of Pb2+ (Struzynska et al., 2005) which may result first in overexcitation and 
finally in desensitization of postsynaptic glutamate receptors, and this way, in increased latency of 
cortical EPs. Mitochondrial damage caused by Pb (Lidsky and Schneider, 2010) may have contrib-
uted to the SS EP latency lengthening directly by energy shortage and indirectly by generating ROS.
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Motivation, determining spontaneous open field locomotor activity, is regulated by mesolimbic 
and mesocortical dopaminergic structures (Alexander et al., 1990). Dopaminergic neurons are 
especially vulnerable to oxidative stress due to the auto-oxidizing tendency of dopamine and 
to the presence of monoamine oxidase producing hydrogen peroxide (Alexi et al., 2000), and 
oxidative stress is a likely consequence of Pb load in the CNS (as outlined above). Vertical mo-
tility is an especially sensitive indicator of striatal dopaminergic activity (Sedelis et al., 2001), 
and significantly diminished rearing was observed in groups PbH6, PbL6+6 and PbH6+6 (with 
anomalous dose-dependence similar to that seen in EP latency). In the same groups, increased 
locomotion was also observed, which was similar to what was reported by Ma et al. (1999) 
from rats following Pb exposure during intra-and extrauterine development, and was explained 
there by decreased cortical D2 receptor level. A possible human analogue is “attention defi-
cit hyperactivity disease” found to be more frequent among children with elevated blood Pb 
(Needleman and Gatsonis, 1990).
CONCLUSION
As xenobiotic heavy metals are found both in the occupational and residential environment 
and in commodities of environmental origin (here: drinking water and food), the health effects 
in individuals exposed to both sources, and in particular the effects on sensitive systems like 
the nervous system, are of especial concern. The more-than-additive neurotoxic interaction of 
nanoparticulate and dissolved Pb demonstrated in the presented work underlines the health rel-
evance of such combined exposures and the necessity of investigations in this field.
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